Work

Activity of combination trametinib/navitoclax in patients with RAS-mutated gynecologic (GYN) cancers in a Phase 1/2 study (LBA 12)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(22)01327-0

Authors: Joyce Liu, Niya Xiong, Elizabeth Lee, Khanh Do, Oladapo Yeku, Catherine Elsier, Suzanne Barry, Michaela Sullivan, Su-Chun Cheng, Joan Brugge, Helen Chen, Ursula Matulonis, Geoffrey Shapiro, Ryan Corcoran

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard University, National Cancer Institute

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4295227095

FWCI: 0.138

Cites:

Cited by: 2

Related to: 10